A tumour-associated macrophage-based signature for deciphering prognosis and immunotherapy response in prostate cancer.

ABSTRACT: For the multistage progression of prostate cancer (PCa) and resistance to immunotherapy, tumour-associated macrophage is an essential contributor. Although immunotherapy is an important and promising treatment modality for cancer, most patients with PCa are not responsive towards it. In addition to exploring new therapeutic targets, it is imperative to identify highly immunotherapy-sensitive individuals. This research aimed to establish a signature risk model, which derived from the macrophage, to assess immunotherapeutic responses and predict prognosis. Data from the UCSC-XENA, GEO and TISCH databases were extracted for analysis. Based on both single-cell datasets and bulk transcriptome profiles, a macrophage-related score (MRS) consisting of the 10-gene panel was constructed using the ge

SUBMITTER: Wang J 

PROVIDER: S-EPMC11490193 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature